Exact Sciences' Cologuard 2.0 trial results fail to sustain stock gains.
TL;DR
Exact Sciences' next-generation Cologuard, a stool-based test for colon cancer, outperformed the original test in a study of 20,000 people, with 94% sensitivity and 91% specificity. The company plans to file for approval of the new test by the end of the year. Despite the positive results, Exact Sciences' stock pulled back 4.8% at the close, settling at 89.78. However, the stock has risen 207% from its recent low point in late October.
Topics:businesshealthcare#cologuard#colon-cancer-screening#exact-sciences#healthcare#sensitivity#specificity
- EXAS Stock Pulls Back Gains Despite Bullish Calls For Cologuard 2.0 | Investor's Business Daily Investor's Business Daily
- Exact Sciences' shares pop on positive Cologuard trial results CNBC Television
- Exact Sciences pads the case for next-gen Cologuard test with improved study results FierceBiotech
- Why Exact Sciences Stock Is Moving Higher After Hours - Exact Sciences (NASDAQ:EXAS) Benzinga
- Exact Sciences touts accuracy of updated Cologuard cancer test, but experts want more data STAT
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Investor's Business Daily